Benefit of early inflow exclusion during living donor liver transplantation for unresectable hepatoblastoma

J Pediatr Surg. 2016 Nov;51(11):1807-1811. doi: 10.1016/j.jpedsurg.2016.04.021. Epub 2016 May 31.

Abstract

Background: Hepatoblastoma (HB) is a highly malignant primary liver tumor in children. Although liver transplantation (LT) is an effective treatment for unresectable HB with good long-term outcomes, post-transplant survival is mainly affected by recurrence, despite adjuvant chemotherapy. Novel strategies are needed to improve the outcomes in patients undergoing LT for unresectable HB.

Patients and methods: Twelve children received LT for unresectable HB. In 9 patients, we applied early exclusion of hepatic inflow (hepatic artery and portal vein) and creation of a temporary portocaval shunt during LT.

Result: There were differences in the duration of and the blood loss during operation as compared with previously reports. The estimated glomerular filtration rate was well preserved at 3, 6, and 12months and the latest follow-up after LT, and the recurrence-free survival was 88.9%.

Conclusion: Early inflow control during LT for unresectable HB may benefit recurrence-free survival by minimizing blood loss and tumor dissemination, preserving renal function and allowing early adjuvant chemotherapy.

Keywords: Hepatoblastoma; Liver transplant; Surgical technique.

MeSH terms

  • Child
  • Child, Preschool
  • Female
  • Hepatic Artery / surgery*
  • Hepatoblastoma / blood supply
  • Hepatoblastoma / mortality
  • Hepatoblastoma / surgery*
  • Humans
  • Infant
  • Infant, Newborn
  • Japan / epidemiology
  • Liver Neoplasms / blood supply
  • Liver Neoplasms / mortality
  • Liver Neoplasms / surgery*
  • Liver Transplantation / methods*
  • Living Donors*
  • Male
  • Portal Vein / surgery*
  • Survival Rate / trends
  • Treatment Outcome